11. Ziprasidone in the Treatment of Bipolar Disorder

  1. Hagop S. Akiskal6 and
  2. Mauricio Tohen7
  1. Thomas L. Schwartz1,
  2. Stephen M. Stahl2,3,
  3. Elizabeth Pappadopulos4,5 and
  4. Onur N. Karayal5

Published Online: 13 APR 2011

DOI: 10.1002/9780470975114.ch11

Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition

Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition

How to Cite

Schwartz, T. L., Stahl, S. M., Pappadopulos, E. and Karayal, O. N. (2011) Ziprasidone in the Treatment of Bipolar Disorder, in Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition (eds H. S. Akiskal and M. Tohen), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470975114.ch11

Editor Information

  1. 6

    International Mood Center, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0603, USA

  2. 7

    Department of Psychiatry, Division of Mood and Anxiety Disorders, University of Texas Health Science Centre at San Antonio, 7730 Floyd Curl Drive, San Antonio, TX 78229, USA

Author Information

  1. 1

    Treatment Resistant Depression and Anxiety Disorders Program, SUNY Upstate Medical University, Syracuse NY 13210, USA

  2. 2

    Department of Psychiatry, University of California San Diego, 9500 Gilman Drive # 9116-A, La Jolla, CA 92093-9116-A, USA

  3. 3

    Department of Psychiatry, University of Cambridge, Cambridge, UK

  4. 4

    Department of Psychiatry Research, Zucker Hillside Hospital, Glen Oaks, NY 11004, USA

  5. 5

    Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA

Publication History

  1. Published Online: 13 APR 2011
  2. Published Print: 15 APR 2011

ISBN Information

Print ISBN: 9780470747216

Online ISBN: 9780470975114

SEARCH

Keywords:

  • bipolar disorder;
  • ziprasidone;
  • treatment;
  • mania;
  • treatment guidelines;
  • antipsychotics;
  • mood stabilizers

Summary

Aripiprazole is an atypical antipsychotic, or a second generation antipsychotic (SGA). As such, it shares the familiar SGA pharmacodynamic profile: antagonism at dopamine D2 and at serotonin 5HT2A receptors. While Ziprasidone is approved for acute and maintenance treatment of bipolar disorder and schizophrenia, in clinical practice, ziprasidone is often used to treat certain bipolar symptoms. This chapter will investigate the proposed mechanism of action of ziprasidone, its clinical indications, the evidence base supporting its use, and finally emphasize how it is most effectively and safely used in treating the bipolar population.